Moleculin Biotech vs Transcode Therapeutics
MBRX and RNAZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MBRX and RNAZ compare
Moleculin Biotech is the larger company, worth 6.2 times as much as Transcode Therapeutics ($8.2M against $1.3M).
Moleculin Biotech scores higher on the StockData Score (6 against 5 for Transcode Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MBRX | RNAZ |
|---|---|---|
| Size and price | ||
| Market cap | $8.2M | $1.3M |
| Share price | $7.87 | $1.32 |
| Change, 1 year | −96.8% | −85.0% |
| Change, 5 years | −100.0% | −100.0% |
| Beta (5Y) | 1.17 | 1.50 |
| Employees | 150K | 12 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.6× | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.37 | 1.97 (better) |
| Altman Z-score | −19.51 | −2.02 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.89% | 3.3% |
Go deeper
- MBRX stock overview
- MBRX income statement
- MBRX valuation and score
- RNAZ stock overview
- RNAZ income statement
- RNAZ valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.